(Yicai) Nov. 9 -- Gilead Sciences aims to introduce more innovative products through the China International Import Expo in the future after feeling the spillover effect of its debut at last year’s trade fair, according to the general manager of the US biopharmaceutical company's Chinese arm.

“The CIIE allows more people to get to know our products and accelerates their launch,” Jin Fangqian, who is also vice-president of Gilead Sciences, told Yicai. “We also hope that the exhibition will help promote multi-party cooperation in chronic hepatitis B management, AIDS prevention, and cancer, and speed up research and development to benefit patients.”

At 500 square meters, Gilead Sciences' booth at this year’s CIIE is five times bigger than it was at last year’s event, he pointed out.

Gilead Sciences has brought along Sunlenca, the world's first long-acting human immunodeficiency virus drug administered twice a year. It was green-lighted in the European Union, and the California-based firm has applied for marketing approval for its tablets and injections in China.

Gilead Sciences is also showcasing 64 ongoing clinical studies from around the world and the progress of its research and development projects in China, which started last year, including 14 clinical research projects covering breast cancer, lung cancer, genitourinary system tumors, digestive tract tumors, and gynecological tumors.

In addition, Gilead Sciences has penned deals with several Chinese hospitals to promote research on hepatitis, tumors as well as HIV prevention and treatment.

Since entering China in 2017, Gilead Sciences has debuted 11 innovative drugs, eight of which have been listed in the national medical insurance catalog. Trodelvy and AmBisome, two of its products shown at last year's CIIE, were approved for marketing in China this year, bringing new treatment options for patients with metastatic triple-negative breast cancer and invasive fungal diseases.

Editor: Martin Kadiev